DGAP-News: Epigenomics AG: Results of Comparative Study between Epigenomics Epi proColon(R) and FIT to be Presented at Digestive Disease Week
(firmenpresse) - DGAP-News: Epigenomics AG / Key word(s): Product Launch/Study
Epigenomics AG: Results of Comparative Study between Epigenomics Epi
proColon(R) and FIT to be Presented at Digestive Disease Week
15.05.2013 / 09:00
---------------------------------------------------------------------
Results of Comparative Study between Epigenomics Epi proColon(R) and FIT to
be Presented at Digestive Disease Week
Berlin, Germany, and U.S.A., May 15, 2013 - Epigenomics AG (Frankfurt Prime
Standard: ECX), the German-American cancer molecular diagnostics company,
today announced that results of the head-to-head comparative study between
its blood-based colorectal cancer (CRC) detection test Epi proColon(R) and
fecal immunochemical testing (FIT) will be presented at a workshop of the
WEO (World Endoscopy Organization) Colorectal Cancer Screening Committee
during this year's DDW (Digestive Disease Week) Conference in Orlando, FL,
U.S.A., on May 17, 2013.
- Epi proColon(R) demonstrates 74% sensitivity in CRC detection and is
non-inferior to FIT
- Blood-based test has potential to increase patient acceptance in CRC
screening according to Prof. David Johnson
The results will be presented by Nicholas Potter, Ph.D., Molecular
Pathology Laboratory Network, Inc. Maryville, TN, U.S.A., on behalf of the
authors, including lead author David A. Johnson, Gastroenterology Division,
Eastern VA Medical School, Norfolk, VA, U.S.A., one of the leading
gastroenterologists in the US and co-author of several CRC screening
guidelines including those of the US Multisociety Task Force and the
American College of Gastroenterology.
In the final analysis of the study results, it was demonstrated that Epi
proColon(R) was able to detect 74% of all evaluable CRC cases in this large
multi-centric clinical study, in comparison to 67% of CRC cases detected by
FIT. Nicholas Potter concluded that it was demonstrated that sensitivity of
the plasma-based methylated Septin9 test is statistically non-inferior to a
widely recommended stool-based screening test (FIT).
Analysis of Septin9 DNA methylation in plasma represents a straightforward,
minimally invasive method to detect all stages of CRC which either alone or
in combination with other screening strategies has the potential to satisfy
unmet needs for increased compliance in the screening population. Prof.
Johnson commented: 'This technology introduces a new opportunity to
increase patient acceptance and compliance with CRC screening. Anything
that increases screening should be viewed as a favorable advance in the
goal to decrease CRC mortality.'
Dr. Uwe Staub, Chief Operating Officer of Epigenomics, commented: 'We are
very pleased with the final study results, which have now been under review
by the FDA since earlier this year. Participation in CRC screening programs
and acceptance of recommended methods, including non-invasive stool-based
tests, are still too low. Based on the achieved non-inferiority in CRC
detection, we believe that Epi proColon(R) has the potential to
significantly drive awareness and acceptance for CRC screening among those
who would otherwise be non-compliant.'
WEO Colorectal Cancer Screening Committee Meeting, DDW Workshop 2013:
The presentation titled 'Use of FIT versus Septin 9: Trial results'
presented by Nicholas T. Potter will be held at the WEO (World Endoscopy
Organization) Colorectal Cancer Screening Committee Meeting, DDW 2013
Workshop, in Orlando, FL, U.S.A. on Friday, May 17, 2013 during the session
'Updates on Screening Methods/ New Tests' which is scheduled for 3.30 pm to
5.10 pm.
- Ends -
Contact Epigenomics AG
Antje Zeise, Manager IR | PR
Epigenomics AG
Kleine Präsidentenstrasse 1
10178 Berlin
Tel. +49 (0) 30 24345 368
ir(at)epigenomics.com
www.epigenomics.com
For US press inquiries:
Epigenomics, Inc.
9700 Great Seneca Highway Rockville
Maryland 20850
pr(at)epigenomics.com
About Epigenomics
Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer earlier
and more accurately, leading to improved outcomes for patients.
Epigenomics' lead product, Epi proColon(R), is a blood-based test for the
early detection of colorectal cancer, which is currently marketed in Europe
and is in development for the U.S.A. The Company's technology and products
have been validated through multiple partnerships with leading global
diagnostic companies and testing laboratories. Epigenomics is an
international company with operations in Europe and the U.S.A.
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.
End of Corporate News
---------------------------------------------------------------------
15.05.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir(at)epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
211119 15.05.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.05.2013 - 09:00 Uhr
Sprache: Deutsch
News-ID 260119
Anzahl Zeichen: 2253
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 321 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Epigenomics AG: Results of Comparative Study between Epigenomics Epi proColon(R) and FIT to be Presented at Digestive Disease Week"
steht unter der journalistisch-redaktionellen Verantwortung von
Epigenomics AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
